IG Digg Blogs

 Ranbaxy Laboratories Limited (Ranbaxy), announced today that the World Health Organisation (WHO), Geneva, has approved and included another of the Company’s Anti Retrovirals (ARV) drug in its pre-qualification list.

The product approved by WHO, Geneva , Abacavir 300 mg tablets, will be manufactured at Ranbaxy’s WHO Pre-Qualified manufacturing site at Paonta Sahib, India.

Abacavir is a nucleoside reverse transcriptase inhibitor and is widely used as part of first line Anti Retroviral treatment around the world.

Abacavir and lamivudine are Anti Viral Drugs play important roles in fighting HIV infection. They are part of a class of drugs called nucleoside reverse transcriptase inhibitors, or NRTIs. This type of drug lowers the number of copies of HIV being made in the body. While EPZICOM is not a cure for HIV, when used as part of your HIV therapy it can help keep the amount of HIV in your body low and your immune system as healthy as possible.

Abacavir (ABC) is the most powerful nucleoside analog reverse transcriptase inhibitor (NARTI) used to treat HIV and AIDS. Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally sensitive to abacavir. When HIV infects a cell, reverse transcriptase copies the viral single stranded RNA genome into a double-stranded viral DNA. The viral DNA is then integrated into the host chromosomal DNA which then allows host cellular processes, such as transcription and translation to reproduce the virus. RTIs block reverse transcriptase’s enzymatic function and prevent completion of synthesis of the double-stranded viral DNA thus preventing HIV from multiplying.

You can read more about Anti Viral Drugs at Indian online Pharmacy

More about Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) (“Ranbaxy”), among the top 10 generic companies in the world and India’s largest pharmaceutical company